Roberta Lanzillo

List of Publications by Year
in descending order

164 papers	4,340 citations	117625 34 h-index	161849 54 g-index
168 all docs	168 docs citations	168 times ranked	5441 citing authors

#	Article	IF	Citations
1	Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy. Multiple Sclerosis Journal, 2022, 28, 93-101.	3.0	13
2	Cognitive trajectories in multiple sclerosis: a long-term follow-up study. Neurological Sciences, 2022, 43, 1215-1222.	1.9	9
3	Disability assessment using Google Maps. Neurological Sciences, 2022, 43, 1007-1014.	1.9	10
4	mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 448-450.	1.9	53
5	Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 57, 103431.	2.0	5
6	The central vein sign helps in differentiating multiple sclerosis from its mimickers: lessons from Fabry disease. European Radiology, 2022, , 1.	4.5	4
7	Mental Health in Multiple Sclerosis During the COVID-19 Outbreak: A Delicate Balance between Fear of Contagion and Resilience. Journal of Clinical Psychology in Medical Settings, 2022, 29, 798-807.	1.4	2
8	Stratification of multiple sclerosis patients using unsupervised machine learning: a single-visit MRI-driven approach. European Radiology, 2022, 32, 5382-5391.	4.5	13
9	Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy). Multiple Sclerosis Journal, 2022, 28, 597-607.	3.0	10
10	Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study. Journal of Clinical Medicine, 2022, 11, 2081.	2.4	6
11	Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis. Neurodegenerative Disease Management, 2022, 12, 109-116.	2.2	5
12	Editorial to Special Issue â€œCognitive Involvement in Multiple Sclerosisâ€• Brain Sciences, 2022, 12, 561.	2.3	0
13	Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 63, 103814.	2.0	2
14	A polynomial regression-based approach to estimate relaxation rate maps suitable for multiparametric segmentation of clinical brain MRI studies in multiple sclerosis. Computer Methods and Programs in Biomedicine, 2022, 223, 106957.	4.7	2
15	Lifestyle and Mediterranean diet adherence in a cohort of Southern Italian patients with Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2021, 47, 102636.	2.0	29
16	Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. European Journal of Neurology, 2021, 28, 1299-1307.	3.3	12
17	The Framingham cardiovascular risk score and 5â€year progression of multiple sclerosis. European Journal of Neurology, 2021, 28, 893-900.	3.3	28
18	Digital work engagement among Italian neurologists. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110296.	2.5	7

#	Article	IF	Citations
19	Diseaseâ€Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Annals of Neurology, 2021, 89, 780-789.	5.3	370
20	Asymptomatic bradycardia after first fingolimod dose in a pediatric patient with multiple sclerosis â€“ a case report. Neurological Sciences, 2021, 42, 37-39.	1.9	4
21	Public Engagement and Neurology: An Update. Brain Sciences, 2021, 11, 429.	2.3	5
22	Physical Exercise Moderates the Effects of Disability on Depression in People with Multiple Sclerosis during the COVID-19 Outbreak. Journal of Clinical Medicine, 2021, 10, 1234.	2.4	10
23	Neuroimaging Correlates of Cognitive Dysfunction in Adults with Multiple Sclerosis. Brain Sciences, 2021, 11, 346.	2.3	23
24	A Retrospective Exploratory Analysis on Cardiovascular Risk and Cognitive Dysfunction in Multiple Sclerosis. Brain Sciences, 2021, 11, 502.	2.3	9
25	Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study. Neurotherapeutics, 2021, 18, 1166-1174.	4.4	24
26	Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 49, 102802.	2.0	25
27	Unraveling Deep Gray Matter Atrophy and Iron and Myelin Changes in Multiple Sclerosis. American Journal of Neuroradiology, 2021, 42, 1223-1230.	2.4	19
28	Needs and Experiences of Children and Adolescents with Pediatric Multiple Sclerosis and Their Caregivers: A Systematic Review. Children, 2021, 8, 445.	1.5	7
29	A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia. Journal of the Neurological Sciences, 2021, 424, 117430.	0.6	1
30	Interplay Between Cognitive and Bowel/Bladder Function in Multiple Sclerosis. International Neurourology Journal, 2021, 25, 310-318.	1.2	6
31	Digital Technology in Clinical Trials for Multiple Sclerosis: Systematic Review. Journal of Clinical Medicine, 2021, 10, 2328.	2.4	19
32	MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study. Journal of the Neurological Sciences, 2021, 424, 117385.	0.6	9
33	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. JAMA Neurology, 2021, 78, 726.	9.0	26
34	Interferon beta for the treatment of multiple sclerosis in the Campania Region of Italy: Merging the real-life to routinely collected healthcare data. PLoS ONE, 2021, 16, e0258017.	2.5	1
35	A Combined Radiomics and Machine Learning Approach to Overcome the Clinicoradiologic Paradox in Multiple Sclerosis. American Journal of Neuroradiology, 2021, 42, 1927-1933.	2.4	9
36	Retinal and Choriocapillary Vascular Changes in Early Stages of Multiple Sclerosis: A Prospective Study. Journal of Clinical Medicine, 2021, 10, 5756.	2.4	8

#	Article	IF	Citations
37	Treatment of multiple sclerosis with rituximab: A multicentric Italianâ€“Swiss experience. Multiple Sclerosis Journal, 2020, 26, 1519-1531.	3.0	38
38	Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study. Multiple Sclerosis and Related Disorders, 2020, 37, 101461.	2.0	14
39	Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?. Neurotherapeutics, 2020, 17, 200-207.	4.4	39
40	The impact of diagnostic criteria and treatments on the 20-year costs for treating relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 38, 101514.	2.0	9
41	Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study. Multiple Sclerosis and Related Disorders, 2020, 38, 101871.	2.0	18
42	COVIDâ€19 pandemic and mental distress in multiple sclerosis: implications for clinical management. European Journal of Neurology, 2020, 28, 3375-3383.	3.3	47
43	Telemedicine in Parkinson's Disease: How to Ensure Patient Needs and Continuity of Care at the Time of COVID-19 Pandemic. Telemedicine Journal and E-Health, 2020, 26, 1533-1536.	2.8	55
44	Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 914-920.	1.9	5
45	A Multiple N-Glucosylated Peptide Epitope Efficiently Detecting Antibodies in Multiple Sclerosis. Brain Sciences, 2020, 10, 453.	2.3	5
46	Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group. Multiple Sclerosis and Related Disorders, 2020, 45, 102394.	2.0	2
47	Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice. Multiple Sclerosis and Related Disorders, 2020, 45, 102452.	2.0	37
48	Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy). BMC Health Services Research, 2020, 20, 797.	2.2	12
49	Cladribine vs other drugs in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	32
50	Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg. Journal of Clinical Medicine, 2020, 9, 4066.	2.4	19
51	Multiple Sclerosis in the Campania Region (South Italy): Algorithm Validation and 2015â€“2017 Prevalence. International Journal of Environmental Research and Public Health, 2020, 17, 3388.	2.6	13
52	Unraveling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 43, 102211.	2.0	6
53	A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting. Neurological Sciences, 2020, 41, 3235-3241.	1.9	9
54	Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials. Frontiers in Neurology, 2020, 11, 489.	2.4	13

#	Article	IF	Citations
55	Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis. Journal of Neurology, 2020, 267, 3008-3020.	3.6	19
56	COVID-19 prevention and multiple sclerosis management: The SAFE pathway for the post-peak. Multiple Sclerosis and Related Disorders, 2020, 44, 102282.	2.0	10
57	First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study. Multiple Sclerosis and Related Disorders, 2020, 42, 102059.	2.0	4
58	Predictors of Nabiximols (SativexÂ®) discontinuation over long-term follow-up: a real-life study. Journal of Neurology, 2020, 267, 1737-1743.	3.6	12
59	The Use of Social Media and Digital Devices Among Italian Neurologists. Frontiers in Neurology, 2020, 11, 583.	2.4	18
60	Peripapillary Vessel Density as Early Biomarker in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 542.	2.4	35
61	2D linear measures of ventricular enlargement may be relevant markers of brain atrophy and long-term disability progression in multiple sclerosis. European Radiology, 2020, 30, 3813-3822.	4.5	18
62	Voxel-based analysis of gray matter relaxation rates shows different correlation patterns for cognitive impairment and physical disability in relapsing-remitting multiple sclerosis. NeuroImage: Clinical, 2020, 26, 102201.	2.7	4
63	Is antibody titer useful to verify the immunization after VZV Vaccine in MS patients treated with Fingolimod? A case series. Multiple Sclerosis and Related Disorders, 2020, 40, 101963.	2.0	14
64	Informing MS patients on treatment options: a consensus on the process of consent taking. Neurological Sciences, 2020, 41, 2249-2253.	1.9	0
65	Prevalence of GLA gene mutations and polymorphisms in patients with multiple sclerosis: A cross-sectional study. Journal of the Neurological Sciences, 2020, 412, 116782.	0.6	2
66	Assessing disability and relapses in multiple sclerosis on tele-neurology. Neurological Sciences, 2020, 41, 1369-1371.	1.9	65
67	Determinants of therapy switch in multiple sclerosis treatment-naÃ¯ve patients: A real-life study. Multiple Sclerosis Journal, 2019, 25, 1263-1272.	3.0	36
68	Retinal vascular density in multiple sclerosis: a 1â€year followâ€up. European Journal of Neurology, 2019, 26, 198-201.	3.3	28
69	Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2019, 36, 101430.	2.0	23
70	Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery. PLoS ONE, 2019, 14, e0222012.	2.5	14
71	Sample Size for Oxidative Stress and Inflammation When Treating Multiple Sclerosis with Interferon-Î²1a and Coenzyme Q10. Brain Sciences, 2019, 9, 259.	2.3	4
72	â€œBetter explanationsâ€in multiple sclerosis diagnostic workup. Neurology, 2019, 92, e2527-e2537.	1.1	44

#	Article	IF	Citations
73	Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-Î²1a-treated multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641881907.	3.5	35
74	Incidence and Predictive Risk Factors of Infective Events in Patients With Multiple Sclerosis Treated With Agents Targeting CD20 and CD52 Surface Antigens. Open Forum Infectious Diseases, 2019, 6, ofz445.	0.9	21
75	Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis. Scientific Reports, 2019, 9, 18074.	3.3	28
76	Determinants of Deep Gray Matter Atrophy in Multiple Sclerosis: A Multimodal MRI Study. American Journal of Neuroradiology, 2019, 40, 99-106.	2.4	39
77	Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey. Journal of Neurology, 2019, 266, 707-716.	3.6	14
78	MRI features suggestive of gadolinium retention do not correlate with Expanded Disability Status Scale worsening in Multiple Sclerosis. Neuroradiology, 2019, 61, 155-162.	2.2	38
79	Therapeutic lag in reducing disability progression in relapsing-remitting multiple sclerosis: 8-year follow-up of two randomized add-on trials with atorvastatin. Multiple Sclerosis and Related Disorders, 2019, 28, 193-196.	2.0	12
80	Normative values of the Raoâ€™s Brief Repeatable Battery in an Italian young adolescent population: the influence of age, gender, and education. Neurological Sciences, 2019, 40, 713-717.	1.9	3
81	Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment. Journal of Neurology, 2019, 266, 361-368.	3.6	9
82	Olfactory function and cognition in relapsingâ€“remitting and secondary-progressive multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 27, 1-6.	2.0	25
83	Optical coherence tomography angiography detects retinal vascular alterations in different phases of multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 300-301.	3.0	11
84	Online validation of the Italian version of the patient determined disease steps scale (PDDS) in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 21, 108-109.	2.0	11
85	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology, 2018, 90, e823-e831.	1.1	102
86	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology, 2018, 90, e832-e839.	1.1	74
87	Cardiovascular profile improvement during Natalizumab treatment. Metabolic Brain Disease, 2018, 33, 981-986.	2.9	5
88	A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study. Journal of Neurology, 2018, 265, 1174-1183.	3.6	23
89	Optical coherence tomography angiography retinal vascular network assessment in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1706-1714.	3.0	88
90	A 8-year retrospective cohort study comparing Interferon-Î² formulations for relapsingâ€remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 19, 50-54.	2.0	8

#	Article	IF	Citations
91	Absence of infratentorial lesions in Fabry disease contributes to differential diagnosis with multiple sclerosis. Brain and Behavior, 2018, 8, e01121.	2.2	13
92	e-Health and multiple sclerosis: An update. Multiple Sclerosis Journal, 2018, 24, 1657-1664.	3.0	63
93	Clinical activity after fingolimod cessation: disease reactivation or rebound?. European Journal of Neurology, 2018, 25, 1270-1275.	3.3	56
94	Cerebellum and cognition in progressive MS patients: functional changes beyond atrophy?. Journal of Neurology, 2018, 265, 2260-2266.	3.6	20
95	Fake news, influencers and health-related professional participation on the Web: A pilot study on a social-network of people with Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2018, 25, 175-178.	2.0	49
96	Affective disorders and Health-Related Quality of Life (HRQoL) in adolescents and young adults with Multiple Sclerosis (MS): the moderating role of resilience. Quality of Life Research, 2017, 26, 727-736.	3.1	55
97	Health-care disparities stemming from sexual orientation of Italian patients with Multiple Sclerosis: A cross-sectional web-based study. Multiple Sclerosis and Related Disorders, 2017, 13, 28-32.	2.0	21
98	The importance of being persistent to multiple sclerosis treatments. Journal of Clinical Neuroscience, 2017, 40, 198-199.	1.5	0
99	Corpus callosum involvement: a useful clue for differentiating Fabry Disease from Multiple Sclerosis. Neuroradiology, 2017, 59, 563-570.	2.2	30
100	CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients. Journal of Neuroimmunology, 2017, 309, 47-50.	2.3	24
101	What should we expect from multiple sclerosis therapy? Results of an integrated analysis of delayedâ€release dimethyl fumarate pivotal trials. European Journal of Neurology, 2017, 24, 661-662.	3.3	2
102	A longitudinal real-life comparison study of natalizumab and fingolimod. Acta Neurologica Scandinavica, 2017, 136, 217-222.	2.1	19
103	Growth hormone/IGF-1 axis longitudinal evaluation in clinically isolated syndrome patients on interferon Î²-1b therapy: stimulation tests and correlations with clinical and radiological conversion to multiple sclerosis. European Journal of Neurology, 2017, 24, 446-449.	3.3	2
104	Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a. Clinical Immunology, 2017, 183, 249-253.	3.2	11
105	A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-Î²1a using RebiSmartâ„¢â€”the FUTURE study. Neurological Sciences, 2017, 38, 1999-2005.	1.9	15
106	Assessing association of comorbidities with treatment choice and persistence in MS. Neurology, 2017, 89, 2222-2229.	1.1	50
107	Grey:white matter ratio at diagnosis and the risk of 10â€year multiple sclerosis progression. European Journal of Neurology, 2017, 24, 195-204.	3.3	12
108	The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests. Multiple Sclerosis Journal, 2017, 23, 1289-1296.	3.0	43

#	Article	IF	Citations
109	Predictors of the 10-year direct costs for treating multiple sclerosis. Acta Neurologica Scandinavica, 2017, 135, 522-528.	2.1	16
110	Cerebellar lobule atrophy and disability in progressive MS. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 1065-1072.	1.9	47
111	Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015. PLoS ONE, 2017, 12, e0169489.	2.5	13
112	Health-Related Coping and Social Interaction in People with Multiple Sclerosis Supported by a Social Network: Pilot Study With a New Methodological Approach. Interactive Journal of Medical Research, 2017, 6, e10.	1.4	36
113	Social Media and Multiple Sclerosis in the Posttruth Age. Interactive Journal of Medical Research, 2017, 6, e18.	1.4	22
114	SPG5 and multiple sclerosis: clinical and genetic overlap?. Acta Neurologica Scandinavica, 2016, 133, 410-414.	2.1	2
115	Google Trends: new evidence for seasonality of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1028-1029.	1.9	39
116	Antibodies from multiple sclerosis patients preferentially recognize hyperglucosylated adhesin of non-typeable Haemophilus influenzae. Scientific Reports, 2016, 6, 39430.	3.3	23
117	Mobitz type I and II atrioventricular blocks during fingolimod therapy. Neurological Sciences, 2016, 37, 1557-1559.	1.9	5
118	The Dress: Transforming a web viral event into a scientific survey. Multiple Sclerosis and Related Disorders, 2016, 7, 41-46.	2.0	16
119	The management of multiple sclerosis by reference centers in south of Italy: a 2011 survey on health demands and needs in Campania region. Neurological Sciences, 2016, 37, 315-322.	1.9	3
120	Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study. Neurology, 2016, 87, 1066-1066.	1.1	2
121	The use of medical-grade cannabis in patients non-responders to Nabiximols. Journal of the Neurological Sciences, 2016, 368, 349-351.	0.6	9
122	Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 10, 90-96.	2.0	21
123	Lack of correlation between extracranial venous abnormalities and multiple sclerosis: a quantitative MRI study. British Journal of Radiology, 2016, 89, 20160321.	2.2	8
124	No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon Î²1b therapy in relapsingâ€“remitting multiple sclerosis (the ARIANNA study). Multiple Sclerosis Journal, 2016, 22, 1163-1173.	3.0	24
125	Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 921-925.	3.0	16
126	In vivo dentate nucleus MRI relaxometry correlates with previous administration of Gadolinium-based contrast agents. European Radiology, 2016, 26, 4577-4584.	4.5	73

#	Article	IF	Citations
127	Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. Expert Opinion on Drug Delivery, 2016, 13, 799-805.	5.0	13
128	Quality of life and cognitive functions in early onset multiple sclerosis. European Journal of Paediatric Neurology, 2016, 20, 158-163.	1.6	36
129	Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression. Multiple Sclerosis Journal, 2016, 22, 659-667.	3.0	107
130	Lesion Load May Predict Long-Term Cognitive Dysfunction in Multiple Sclerosis Patients. PLoS ONE, 2015, 10, e0120754.	2.5	31
131	Uric acid in relapsingâ€“remitting multiple sclerosis: a 2-year longitudinal study. Journal of Neurology, 2015, 262, 961-967.	3.6	29
132	Uric acid: a potential biomarker of multiple sclerosis and of its disability. Clinical Chemistry and Laboratory Medicine, 2015, 53, 753-9.	2.3	38
133	The Framingham cardiovascular risk score in multiple sclerosis. European Journal of Neurology, 2015, 22, 1176-1183.	3.3	54
134	Vitamin K cream reduces reactions at the injection site in patients with relapsingâ€“remitting multiple sclerosis treated with subcutaneous interferon beta â€“ VIKING study. Multiple Sclerosis Journal, 2015, 21, 1215-1216.	3.0	6
135	JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level. Therapeutics and Clinical Risk Management, 2014, 10, 807.	2.0	11
136	Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study. Multiple Sclerosis Journal, 2014, 20, 220-226.	3.0	30
137	Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab. JAMA Neurology, 2014, 71, 954.	9.0	50
138	Effects of Bacille Calmette-GuÃ©rin after the first demyelinating event in the CNS. Neurology, 2014, 82, 41-48.	1.1	128
139	Internal Jugular Vein Blood Flow in Multiple Sclerosis Patients and Matched Controls. PLoS ONE, 2014, 9, e92730.	2.5	18
140	Chronic cerebrospinal venous insufficiency in multiple sclerosis: a highly prevalent age-dependent phenomenon. BMC Neurology, 2013, 13, 20.	1.8	19
141	Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice. Neurological Sciences, 2013, 34, 521-528.	1.9	20
142	Multiple Sclerosis: Cerebral Circulation Time. Radiology, 2012, 262, 947-955.	7.3	42
143	Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study. Acta Neurologica Scandinavica, 2012, 126, 306-314.	2.1	25
144	Biochemical Parameters Alterations in Multiple Sclerosis: A Longitudinal Study and Review of the Literature. Pharmacology & Pharmacy, 2012, 03, 248-253.	0.7	1

#	Article	IF	Citations
145	Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients. European Journal of Neurology, 2011, 18, 1402-1406.	3.3	17
146	Predictive factors of neutralizing antibodies development in relapsing-remitting multiple sclerosis patients on interferon Beta-1b therapy. Neurological Sciences, 2011, 32, 287-292.	1.9	4
147	Atorvastatin Combined To Interferon to Verify the Efficacy (ACTIVE) in relapsingâ€" remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Multiple Sclerosis Journal, 2010, 16, 450-454.	3.0	79
148	A voxel-based morphometry study of disease severity correlates in relapsingâ€" remitting multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 45-54.	3.0	45
149	Early detection of biventricular involvement in myotonic dystrophy by tissue Doppler. International Journal of Cardiology, 2007, 118, 227-232.	1.7	19
150	Multiple sclerosis and headache co-morbidity. A case-control study. Neurological Sciences, 2007, 28, 133-135.	1.9	54
151	Grey matter loss in relapsingâ€"remitting multiple sclerosis: A voxel-based morphometry study. NeuroImage, 2006, 29, 859-867.	4.2	167
152	Modifications of brain tissue volumes in facioscapulohumeral dystrophy. NeuroImage, 2006, 32, 1237-1242.	4.2	26
153	Neuropsychological assessment, quantitative MRI and ApoE gene polymorphisms in a series of MS patients treated with IFN beta-1b. Journal of the Neurological Sciences, 2006, 245, 141-145.	0.6	27
154	Early onset calpainopathy with normal non-functional calpain 3 level. Developmental Medicine and Child Neurology, 2006, 48, 304-306.	2.1	15
155	Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis. European Journal of Neurology, 2006, 13, 1014-1021.	3.3	30
156	A new POLG1 mutation with peo and severe axonal and demyelinating sensoryâ€"motor neuropathy. Journal of Neurology, 2006, 253, 869-874.	3.6	23
157	The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis. Journal of Neuroimmunology, 2005, 167, 131-137.	2.3	56
158	Analysis of Dystrophin Gene Deletions Indicates that the Hinge III Region of the Protein Correlates with Disease Severity. Annals of Human Genetics, 2005, 69, 253-259.	0.8	35
159	Epileptic seizures in multiple sclerosis: clinical and EEG correlations. Neurological Sciences, 2003, 24, 322-328.	1.9	49
160	Brain tissue volume changes in relapsing-remitting multiple sclerosis: correlation with lesion load. NeuroImage, 2003, 18, 360-366.	4.2	82
161	Two new mutations in the myophosphorylase gene in Italian patients with McArdle's disease. Neuromuscular Disorders, 2002, 12, 498-500.	0.6	7
162	Aphasia as a rare presentation of monosymptomatic demyelinating disease: case report and review of the literature. Neurological Sciences, 2002, 23, 79-82.	1.9	19

#	Article	IF	Citations
163	Transient Muteness Followed by Dysarthria in Patients with Pontomesencephalic Stroke. Cerebrovascular Diseases, 1999, 9, 124-126.	1.7	11
164	Multiple Sclerosis And Maternity: A Psychological Explorative Qualitative Research. Qualitative Report, 0, , .	0.1	1